Maha Katabi - Sep 19, 2023 Form 4 Insider Report for RayzeBio, Inc. (RYZB)

Role
Director
Signature
/s/ Jeff Woodley, Attorney-in-fact
Stock symbol
RYZB
Transactions as of
Sep 19, 2023
Transactions value $
$8,499,996
Form type
4
Date filed
9/21/2023, 05:10 PM
Previous filing
Sep 14, 2023
Next filing
Nov 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYZB Common Stock Conversion of derivative security +974K 974K Sep 19, 2023 See footnote F1, F2
transaction RYZB Common Stock Conversion of derivative security +974K 974K Sep 19, 2023 See footnote F1, F3
transaction RYZB Common Stock Purchase $4.25M +236K +24.25% $18.00* 1.21M Sep 19, 2023 See footnote F2, F4
transaction RYZB Common Stock Purchase $4.25M +236K +24.25% $18.00* 1.21M Sep 19, 2023 See footnote F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYZB Series D Convertible Preferred Stock Conversion of derivative security -974K -100% 0 Sep 19, 2023 Common Stock 974K By Sofinnova Venture Partners X, L.P. F1, F2
transaction RYZB Series D Convertible Preferred Stock Conversion of derivative security -974K -100% 0 Sep 19, 2023 Common Stock 974K By Sofinnova Venture Partners XI, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Every 5.141 shares of Series D Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
F2 The shares are held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
F3 The shares are held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
F4 The shares were purchased in the Issuer's initial public offering.